OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-1.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$471M
AUM Growth
+$471M
(-12%)
Cap. Flow
-$18.7M
Cap. Flow
% of AUM
-3.96%
Top 10 Holdings %
Top 10 Hldgs %
58.75%
Holding
54
New
6
Increased
11
Reduced
10
Closed
15
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$9.16M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$8.7M |
| 3 |
Ginkgo Bioworks
DNA
|
$7.73M |
| 4 |
Merus
MRUS
|
$6.92M |
| 5 |
Hyperfine
HYPR
|
$5.52M |
Top Sells
| 1 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$7.17M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$6.98M |
| 3 |
Celldex Therapeutics
CLDX
|
$5.45M |
| 4 |
AFIB
Acutus Medical, Inc. Common Stock
AFIB
|
$5.22M |
| 5 |
Keros Therapeutics
KROS
|
$5.08M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Codexis
CDXS
$246M
| $42.1M | 8.92% | 1,345,000 | – | – |
|
2
Ocular Therapeutix
OCUL
$2.12B
| $41.6M | 8.83% | 5,974,800 -505,200 | -8% | -$3.52M |
|
|
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
| $35.9M | 7.61% | 5,580,000 +550,000 | +11% | +$3.54M |
|
|
4
Celldex Therapeutics
CLDX
$1.47B
| $32.6M | 6.92% | 844,000 -141,000 | -14% | -$5.45M |
|
5
Harrow
HROW
$1.44B
| $28.4M | 6.02% | 3,285,000 | – | – |
|
6
Cytokinetics
CYTK
$4.23B
| $26.4M | 5.61% | 580,000 | – | – |
|
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $20.6M | 4.36% | 724,400 +322,287 | +80% | +$9.16M |
|
8
Protara Therapeutics
TARA
$120M
| $18M | 3.82% | 2,650,000 +91,528 | +4% | +$622K |
|
9
Semler Scientific
SMLR
$439M
| $15.8M | 3.34% | 172,000 -53,566 | -24% | -$4.91M |
|
10
Stereotaxis
STXS
$261M
| $15.7M | 3.32% | 2,526,500 | – | – |
|
|
11
Keros Therapeutics
KROS
$618M
| $15.5M | 3.3% | 265,750 -86,750 | -25% | -$5.08M |
|
12
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $12.1M | 2.56% | 1,025,000 -285,000 | -22% | -$3.35M |
|
13
Protagonist Therapeutics
PTGX
$3.67B
| $11.7M | 2.48% | 342,000 +11,778 | +4% | +$403K |
|
14
ProQR Therapeutics
PRQR
$237M
| $11.5M | 2.44% | 1,435,510 +11,310 | +0.8% | +$90.6K |
|
15
Eton Pharmaceutcials
ETON
$464M
| $10.2M | 2.17% | 2,385,000 -703,100 | -23% | -$3.02M |
|
16
Sutro Biopharma
STRO
$72.7M
| $10.1M | 2.15% | 680,000 +142,200 | +26% | +$2.12M |
|
|
17
Merus
MRUS
$4.98B
| $10.1M | 2.14% | 317,800 +217,550 | +217% | +$6.92M |
|
18
Larimar Therapeutics
LRMR
$310M
| $9.53M | 2.02% | 883,602 +50,795 | +6% | +$548K |
|
19
Fortress Biotech
FBIO
$76.8M
| $9.38M | 1.99% | 3,750,000 | – | – |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.7M | 1.85% | +330,000 | New | +$8.7M |
|
|
TCON
21
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $8.46M | 1.79% | 3,055,000 +536,629 | +21% | +$1.49M |
|
|
22
Ginkgo Bioworks
DNA
$750M
| $7.73M | 1.64% | +929,780 | New | +$7.73M |
|
23
Vaxcyte
PCVX
$4B
| $7.51M | 1.59% | 315,800 -37,600 | -11% | -$895K |
|
24
MacroGenics
MGNX
$112M
| $7.42M | 1.57% | 462,000 | – | – |
|
25
Xoma
XOMA
$392M
| $7.06M | 1.5% | 338,350 | – | – |
|